IL122174A - DNA encoding the CD40L mutine and CD40L polypeptide encoded by the above DNA - Google Patents

DNA encoding the CD40L mutine and CD40L polypeptide encoded by the above DNA

Info

Publication number
IL122174A
IL122174A IL12217496A IL12217496A IL122174A IL 122174 A IL122174 A IL 122174A IL 12217496 A IL12217496 A IL 12217496A IL 12217496 A IL12217496 A IL 12217496A IL 122174 A IL122174 A IL 122174A
Authority
IL
Israel
Prior art keywords
cd40l
dna
leu
seq
ser
Prior art date
Application number
IL12217496A
Other languages
English (en)
Hebrew (he)
Other versions
IL122174A0 (en
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/477,733 external-priority patent/US5981724A/en
Priority claimed from US08/484,624 external-priority patent/US5962406A/en
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of IL122174A0 publication Critical patent/IL122174A0/xx
Publication of IL122174A publication Critical patent/IL122174A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C12N1/18—Baker's yeast; Brewer's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Botany (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Amplifiers (AREA)
  • Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Reverberation, Karaoke And Other Acoustics (AREA)
IL12217496A 1995-06-07 1996-06-06 DNA encoding the CD40L mutine and CD40L polypeptide encoded by the above DNA IL122174A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/477,733 US5981724A (en) 1991-10-25 1995-06-07 DNA encoding CD40 ligand, a cytokine that binds CD40
US08/484,624 US5962406A (en) 1991-10-25 1995-06-07 Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
PCT/US1996/009632 WO1996040918A2 (en) 1995-06-07 1996-06-06 Novel cd40l mutein

Publications (2)

Publication Number Publication Date
IL122174A0 IL122174A0 (en) 1998-04-05
IL122174A true IL122174A (en) 2004-07-25

Family

ID=27045653

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12217496A IL122174A (en) 1995-06-07 1996-06-06 DNA encoding the CD40L mutine and CD40L polypeptide encoded by the above DNA

Country Status (15)

Country Link
EP (1) EP0832229B1 (no)
JP (1) JP3279573B2 (no)
KR (1) KR100453314B1 (no)
AT (1) ATE257858T1 (no)
AU (1) AU693713B2 (no)
CA (1) CA2222914C (no)
DE (1) DE69631331T2 (no)
DK (1) DK0832229T3 (no)
ES (1) ES2214541T3 (no)
IL (1) IL122174A (no)
MX (1) MX9709447A (no)
NO (1) NO317735B1 (no)
NZ (1) NZ311335A (no)
PT (1) PT832229E (no)
WO (1) WO1996040918A2 (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
AU705647B2 (en) * 1996-07-10 1999-05-27 Immunex Corporation Method of activating dendritic cells
EP2314695A3 (en) 1996-12-23 2011-12-21 Immunex Corporation Ligand for receptor activator of NF-kappa B, ligand is member of TNF superfamily
DE69939822D1 (de) 1998-05-14 2008-12-11 Immunex Corp Verfahren zur hemmung der wirkung der osteoklasten
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
US20040053249A1 (en) * 2000-05-26 2004-03-18 Junko Tohma Fas ligand-fused proteins
LT1434871T (lt) 2001-09-20 2017-04-10 Immunex Corporation Heteromerinius polipeptidus ekspresuojančių ląstelių atranka
KR20050101554A (ko) 2003-02-14 2005-10-24 바이오겐 아이덱 엠에이 인코포레이티드 외인성 분자를 일시적으로 또는 안정하게 발현하기 위한발현 카세트 및 발현 벡터
JP3936673B2 (ja) * 2003-06-02 2007-06-27 国立大学法人群馬大学 Ｃｄ４７部分ペプチドと抗ｓｈｐｓ−１モノクロナール抗体
EP1673389A2 (en) * 2003-10-10 2006-06-28 Xencor Inc. Novel variants of cd40l protein
NZ554520A (en) 2004-10-22 2010-03-26 Amgen Inc Methods for refolding of recombinant antibodies
CN101663390B (zh) 2006-09-13 2013-10-23 Abbvie公司 使用非动物源水解产物的分批补料细胞培养方法
EP2500414A1 (en) 2006-09-13 2012-09-19 Abbott Laboratories Cell culture improvements
MY183797A (en) 2006-09-18 2021-03-16 Univ Arkansas Compositions and methods of enhancing immune responses
US8222016B2 (en) 2007-06-29 2012-07-17 Daiichi Sankyo Company, Limited Recombinant C-terminal α-amidating enzyme derivative
CA2698809C (en) 2007-09-14 2023-10-17 Amgen Inc. Homogeneous antibody populations
EP2214840B1 (en) 2007-10-30 2015-05-06 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
DK2214701T3 (en) 2007-11-01 2016-12-12 Univ Arkansas CONFIGURATIONS AND METHODS FOR IMPROVING THE IMMUNE RESPONSES TO Eimeria
BRPI0906490A2 (pt) 2008-01-15 2015-07-14 Abbott Lab Vetores de expressão de mamífero melhorados e uso dos mesmos
PT2501822T (pt) 2009-11-17 2017-10-18 Squibb & Sons Llc Métodos para produção de proteínas melhorada
JP6242050B2 (ja) 2010-01-21 2017-12-06 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー 免疫応答を増強するワクチンベクターおよび方法
BR112012031211A2 (pt) 2010-06-09 2018-01-30 Univ Arkansas métodos e vacina para reduzir a infecção causada pelo campylobacter
BR112015019283B1 (pt) 2013-02-14 2023-12-19 The Board Of Trustees Of The University Of Arkansas Composições e métodos de aprimoramento de respostas imunes à eiméria ou infecção por eiméria limitadora
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
AR095313A1 (es) 2013-03-15 2015-10-07 Univ Arkansas Composiciones y métodos para aumentar la respuesta inmune contra patógenos entéricos
CN114605549A (zh) 2015-08-05 2022-06-10 詹森生物科技公司 抗cd154抗体及其使用方法
WO2017083604A1 (en) 2015-11-12 2017-05-18 Amgen Inc. Triazine mediated pharmacokinetic enhancement of therapeutics
TWI843057B (zh) 2016-05-03 2024-05-21 阿肯色州大學董事會 包含免疫刺激性及抗原性多肽的酵母菌疫苗載體以及其使用方法
IL300591A (en) 2016-05-11 2023-04-01 Amgen Inc Direct selection of cells expressing high levels of heteromeric proteins using intergenic glutamine synthetase complementation vectors
MA44993A (fr) * 2016-05-13 2019-03-20 Medimmune Llc Polypeptides de fusion cd40l-fc et procédés d'utilisation associés

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2227513T5 (es) * 1991-10-25 2009-04-01 Immunex Corporation Citoquina novedosa.
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
ES2198414T3 (es) * 1992-10-23 2004-02-01 Immunex Corporation Procedimientos para preparar proteinas oligomericas solubles.

Also Published As

Publication number Publication date
DK0832229T3 (da) 2004-05-03
DE69631331T2 (de) 2004-11-18
CA2222914A1 (en) 1996-12-19
WO1996040918A3 (en) 1997-01-23
NZ311335A (en) 1998-05-27
AU6263896A (en) 1996-12-30
NO975437D0 (no) 1997-11-26
IL122174A0 (en) 1998-04-05
JPH11504819A (ja) 1999-05-11
JP3279573B2 (ja) 2002-04-30
AU693713B2 (en) 1998-07-02
EP0832229A2 (en) 1998-04-01
PT832229E (pt) 2004-06-30
NO975437L (no) 1998-02-06
WO1996040918A2 (en) 1996-12-19
DE69631331D1 (de) 2004-02-19
NO317735B1 (no) 2004-12-13
ATE257858T1 (de) 2004-01-15
EP0832229B1 (en) 2004-01-14
KR19990022141A (ko) 1999-03-25
ES2214541T3 (es) 2004-09-16
CA2222914C (en) 2002-04-02
KR100453314B1 (ko) 2004-12-17
MX9709447A (es) 1998-02-28

Similar Documents

Publication Publication Date Title
AU693713B2 (en) CD40L mutein
US6264951B1 (en) Methods of inhibiting CD40L binding to CD40 with soluble monomeric CD40L
US6290972B1 (en) Method of augmenting a vaccine response by administering CD40 ligand
MXPA97009447A (en) New muteina cd
AU661360B2 (en) Novel cytokine
US5961974A (en) Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
Nakamura et al. Heterodimerization of the IL-2 receptor β-and γ-chain cytoplasmic domains is required for signalling
US6165476A (en) Fusion proteins with an immunoglobulin hinge region linker
EP1229047B1 (en) IL-1 Receptor fusion proteins used as antagonists and methods of making and using
US5488032A (en) Method of using soluble human interleukin-1 receptors to suppress inflammation
US20040006006A9 (en) CD40-Ligand lacking native-pattern glycosylation
USRE35450E (en) Soluble human interleukin-1 receptors, compositions and method of use
ES et al. NEUE CYTOKINE NOUVELLE CYTOKINE

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees